Company profile
Cellesce Limited
Cellesce Growing and scale up of patient derived organoids
Cellesce Limited is a UK company with status active founded in 2013 based in Wales.
Corporate ownership
Updated 06 Jun 2026 16:52
Company events
Reference milestones and recent Companies House filing stream events.
Confirmation statement due
Confirmation DueNext confirmation statement due date
Accounts due
Accounts DueNext accounts due date
Confirmation statement filed
ConfirmationLast confirmation statement made up date
Capital Statement Capital Company With Date Currency Figure
CapitalSH19 | Transaction MzUxNDEwNjEwMWFkaXF6a2N4 | Paper/PDF filed
Published 08 Apr 2026 23:09
Capital Statement Capital Company With Date Currency Figure
CapitalSH19 | Transaction MzQ5MjU4MTE3NWFkaXF6a2N4 | Paper/PDF filed
Published 03 Apr 2026 23:24
Accounts filed
AccountsLast accounts made up date
Accounts With Accounts Type Small
Accounts PDF pendingAA | Transaction MzQzNDE1MDc5M2FkaXF6a2N4 | Paper/PDF filed
Published 05 Sep 2024 06:04
Incorporated
InceptionCompany registered at Companies House
Public funding
Projects
Scale-up of breast and colorectal cancer organoids for high throughput screening
29 Apr 2021 to 29 Apr 2023
There is an urgent and unmet medical need to discover new cancer therapeutics that specifically target diseased cells and minimise adverse side-effects. One of the hurdles to be overcome in identifying new treatments is the availability of a lab-based test system that can accurately predict the efficacy of novel compounds for further clinical development....
Cardiff University and Cellesce Limited - P2
1 Mar 2021 to 31 Aug 2023
To implement an advanced data analysis pipeline to identify key morphometric signatures from 3D images of screened organoids in drug trials and to classify organoid response for the assessment of therapeutic efficacy for application in the pharmaceutical industry.
Fully synthetic animal-free scaffolds: the future of sustainable and scalable organoid culture
1 Jan 2021 to 30 Sep 2021
Organoids are 3-dimensional (3D) clusters of stem cells that come together and emulate the microenvironment within individual organs, whether that be liver, kidney, heart, gut or other specific organs. Essentially, they can be viewed as miniature, simplified organs. They typically range in size from a few micrometers to five millimeters and there are pote...
Commercialisation of Patient-derived breast cancer organoids for drug discovery
1 Jun 2020 to 30 Nov 2020
no public description
Cardiff University and Cellesce Limited - P1
1 Aug 2019 to 31 Dec 2022
To develop novel, real-time, cell ‘happiness’ assays to allow optimisation of the growth of patient samples in 3D mini organ-like cultures. These 'organoids' can be used in drug discovery and genetics research.
Patient-derived breast cancer organoids to transform drug discovery screening assays
1 Jul 2018 to 31 Oct 2020
"There is an urgent and unmet medical need to discover and develop new disease-modifying breast cancer therapeutics that specifically target diseased cells and minimise adverse side-effects. One of the hurdles to be overcome in identifying new treatments is the availability of a test system that accurately predicts the efficacy of novel compounds for furt...
Bioreactor and Bioprocessing of organoids to enable their market-wide drug screening application
1 Sep 2014 to 29 Feb 2016
Organoid culture is a new technique that, unlike the use of cell lines, maintains tumour properties in the lab. Organoid cultures should improve the rate at which new drugs are discovered since they should lower the number of ineffective drugs that make their way through animal testing; this will directly lead to new, more effective drugs plus reductions ...